Background and aim Soluble c-erbB-2 oncoprotein has been proven as a useful marker in the management of breast cancer patients, but its value in diagnostics and follow-up of colorectal cancer patients remains controversial. The aim of this study was to evaluate the usefulness of serum c-erbB-2 monitoring in diagnostics and prediction of disease outcome in rectal cancer patients. Materials and methods Serum samples from 88 patients with rectal adenocarcinoma before surgery and from 41 healthy controls were tested for the presence of c-erbB-2 oncoprotein by ELISA, and the patients were followed up for at least 5 years after the surgery. Results Preoperative serum c-erbB-2 levels were significantly higher in stage IV patients than in healthy controls (P<0.001) and did not show correlation with preoperative CEA levels. Elevated preoperative serum c-erbB-2 levels showed relatively high specificity (88%) and low sensitivity (44%) in the diagnosis of rectal cancer. Elevated preoperative oncoprotein levels were predictive neither for overall survival nor for development of local recurrence/distant metastases. Conclusion Although preoperative serum c-erbB-2 levels were significantly higher in rectal cancer patients than in healthy controls, the soluble c-erbB-2 does not seem to be useful in the diagnosis of rectal cancer due to its low sensitivity. Preoperative serum levels of this oncoprotein were predictive neither for overall survival nor for local recurrence/distant metastases in rectal cancer patients.
Introduction
The c-erbB-2 (HER-2/neu) oncoprotein is a 185-kD epidermal growth factor receptor-like transmembrane glycoprotein with tyrosine kinase activity. The extracellular domain of c-erbB-2 can be shed from cancer cells in cultures overexpressing c-erbB-2 [1] . The antigen was also found in the sera of patients with breast [2, 3] , hepatocellular [4] , gastric [5] , and ovarian cancers [6] . Possible clinical significance of soluble c-erbB-2 has been so far more extensively studied only in breast cancer patients, where its levels were hypothesized to correlate with the disease stage [7] , with response to hormone therapy [8] and chemotherapy [9] , and predict for shortened survival [7] . Data related to serum c-erbB-2 levels in patients with rectal cancer is, to our knowledge, limited to six reports [10] [11] [12] [13] [14] [15] . Two of these reports are based on a small number of patients [10, 11] , and no one has been dealing particularly with rectal cancer patients. The aim of this study was to assess the association of preoperative serum c-erbB-2 levels with tumor stage, local recurrence, distant metastases, and overall survival of rectal cancer patients.
Materials and methods

Subjects
Healthy controls Forty-one healthy volunteers, aged 25-75 years (median 53), among them were 20 women (49%) and 21 men (51%), served as blood donors for the determination of soluble c-erbB-2.
Patients A cohort of 88 patients with primary rectal adenocarcinoma, aged 28-79 years (median 60), among the members of the group were 35 women (40%) and 53 men (60%), was included in this prospective study. Preoperative diagnosis was established by standard diagnostic procedures, i.e., endoscopy and radiography, and when required by ultrasonography and computerized tomography. Regarding tumor localization, all patients had rectal cancer; colon, cecal, and anal cancers were not included in the study. All primary tumors were resected and pathohistologically confirmed to be adenocarcinomas. Tumor staging was carried out by AJCC Cancer Staging system [16] . There were nine (10%) stage 0 patients, 24 (27%) stage I patients, 17 (19%) stage II patients, 20 (23%) stage III patients, and 18 (21%) stage IV patients (13 with liver, 1 with pulmonary, 1 with brain, 2 with bone, and 1 with peritoneal metastases). In the first year after surgery, the patients were followed up according to a standardized protocol that included laboratory tests (routine blood cell count, CEA), ultrasonography of abdomen, computerized tomography of the pelvis, chest radiography, and rectoscopy at 3-month intervals in the first year, at 6-month intervals in the second year after surgery, and at yearly intervals afterward. The study was carried out in compliance with the Helsinki Declaration II [17] , and informed consent was obtained from all patients and healthy controls before their enrollment in the study.
Methods
Serum c-erbB-2 determination Blood samples were drawn by venepuncture 1-3 days before surgery between 7:00 and 8:00 a.m. and were centrifuged. Sera were separated and stored in aliquots at −20°C until assayed. Levels of soluble c-erbB-2 oncoprotein were determined by enzymelinked immunosorbent assay (Quantitative ELISA Assay neu/c-erbB-2, Oncogene Research Products, Calbiochem, USA) using monoclonal antibody specific for human p185 neu/c-erbB-2 as well as for its extracellular fragment p105 (Ab-3). Results were expressed in human neu units (HNU) per milliliter.
Serum CEA determination Serum CEA levels were determined in serum samples obtained and stored as described above. An immunoradiometric assay for the quantitative determination of carcinoembryonic antigen in human serum or plasma was used (ELSA2-CEA, Cat. # 38C17, CIS Bio International, France), with the level of 5 ng/ml as a cut-off value.
Statistical analysis
The results are presented as medians with corresponding interquartile ranges and were analyzed by Kruskal-Wallis and Mann-Whitney U post hoc tests with correction for multiple testing. P values <0.05 were considered statistically significant. Differences between categories were analyzed by χ 2 test. Correlation between c-erbB-2 and CEA levels was analyzed by the Fisher's exact test and by calculation of Pearson correlation coefficient. Survival rates were calculated by the Kaplan-Meier method and compared using the log-rank test, with P<0.05 being considered statistically significant. Predictive value of preoperative c-erbB-2 levels was tested by ROC analysis.
Results
On the basis of measurements in healthy volunteers, the concentration of 51.5 HNU/ml c-erbB-2 was used as a cutoff value by the ROC analysis. Specificity, sensitivity, accuracy, false positive/negative ratios, and positive/negative predictive values of soluble c-erbB-2 in diagnosis of rectal cancer are shown in Table 1 . With 88% specificity at the selected cut-point, the sensitivity was 44% (39 out of 88 patients with elevated c-erbB-2 values) and was lower than the sensitivity of CEA (48%, 42 out of 88 patients with elevated preoperative CEA levels, Table 2 ) in the diagnosis of rectal cancer. There was no significant correlation between preoperative serum c-erbB-2 and CEA levels (r=0.33, P=0.086). Preoperative serum levels of c-erbB-2 were significantly higher in stage IV patients than in healthy controls, while there were no significant differences between patients with other disease stages and healthy individuals ( Table 2) . Taking the value of 51.5 HNU/ml c-erbB-2 as a cut-point, significantly more positive findings were noted among stage IV than in stage 0 patients; there were no significant differences between stages I-III and stage 0 patients (Table 3) . During the 5-year follow-up (mean follow-up time 63.4 months), 45 out of 70 patients who were disease-free after primary tumor resection remained disease-free, 10 developed local recurrence, and 15 developed distant metastases. There was no difference in preoperative serum c-erbB-2 levels between disease-free patients and those who developed local recurrence, but in those who developed distant metastases, preoperative serum c-erbB-2 levels were significantly higher than in those who were disease-free (Fig. 1) . The proportion of patients with preoperative elevated c-erbB-2 values (>51.5 HNU/ml) was also significantly higher among patients who developed distant metastases in comparison with those who remained (Fig. 1) . Cut-off value of 51.5 HNU c-erbB-2/ml was also used for the survival analysis. Patients with elevated preoperative oncoprotein levels showed slightly shorter but nonsignificant overall survival compared to those with normal oncoprotein levels (42.9 months, 95% CI=34.5-51.3 vs 45.0 months, 95% CI=38.9-51.1, respectively; log rank test=0.63; P=0.426; Fig. 2 ). ROC analysis of elevated, preoperative oncoprotein predictive value gave AUC of 0.540 (95% CI=0.386-0.694) for local recurrence and AUC of 0.583 (95% CI=0.444-0.723) for distant metastases.
Discussion
Preoperative serum c-erbB-2
In this study, we detected significantly higher preoperative serum c-erbB-2 levels in stage IV rectal cancer patients before surgery than in healthy individuals indicating a possible role for c-erbB-2 in colorectal cancer progression, as already suggested in two recently published reports [14, 15] . Regarding the diagnostic value of c-erbB-2, its sensitivity was the same (44%) as reported by Polychronidis et al. (44%) [15] and higher than the one reported by Tsigris et al. (41%) [14] . The specificity found in our study was also almost the same as in study of Polychronidis et al.
(88 vs 89%, respectively) [15] . However, it was lower than reported by Tsigris et al. (97%) [14] probably because the sensitivity in their study was lower than in ours (41 vs 44%, respectively). Significantly more patients with elevated c-erbB-2 were detected among those with distant metastases than among those with localized disease. Because the sensitivity of serum c-erbB-2 in the diagnosis of rectal cancer was lower than the sensitivity of CEA, and because there was no correlation between serum levels of these two markers, serum c-erbB-2 does not seem to be of any value in increasing the sensitivity of rectal cancer diagnosis.
Preoperative serum c-erbB-2 and survival Although a tendency for shorter overall survival of patients with elevated preoperative serum c-erbB-2 levels when compared to those with normal levels was noted, this difference was not significant (log rank test, P=0.426). Polychronidis et al. [15] reported similar results in their series of 52 colorectal cancer patients and ascribed the lack of significance to too small number of patients. However, we also failed to demonstrate statistical significance although our cohort comprised 88 patients. On the other hand, Tsigris et al. [14] demonstrated the correlation of elevated serum c-erbB-2 levels with overall survival in their series of 63 colorectal cancer patients. This difference could be explained by more restrictive cut-off value for c-erbB-2 levels and correspondingly higher sensitivity obtained in our and Polychronidis than in Tsigris' study. In addition, our cohort was more homogeneous with respect to tumor localization, comprising only rectal cancer patients. We also did not find elevated preoperative serum c-erbB-2 levels to be predictive neither for local recurrence nor for distant metastases. Chamberlain et al. [13] also reported that elevated serum c-erbB-2 concentrations were not predictive of disease outcome in their cohort of 88 colorectal cancer patients. However, they did not specify whether this applied to overall survival or to a disease recurrence. In conclusion, elevated serum c-erbB-2 levels showed high specificity and positive predictive value and low sensitivity and negative predictive value so that these levels do not seem to be useful as tumor markers in rectal cancer diagnosis. They also do not seem to be useful predictors of neither overall survival nor local recurrence/distant metastases in rectal cancer patients.
